FDAnews
www.fdanews.com/articles/101188-vivus-begins-conquer-trial-for-qnexa

Vivus Begins CONQUER Trial for Qnexa

November 16, 2007

Vivus has started the second of two Phase III studies of Qnexa in overweight and obese patients with co-morbidities, including hypertension, dyslipidemia and Type 2 diabetes.

The randomized, double-blind, placebo-controlled CONQUER study will enroll 2,500 patients with a body mass index (BMI) of 27–45 and those with Type 2 diabetes, regardless of BMI. Subjects will receive once-a-day treatment with mid-dose Qnexa (7.5 mg phentermine/46 mg topiramate), full-strength Qnexa (15 mg phentermine/92 mg topiramate) or placebo.

The studies will evaluate the differences between treatments from baseline to the end of the treatment period in mean percent weight loss and in the percentage of subjects achieving weight loss of 5 percent or more, Vivus said.